BEAT vs IDXX vs ZTS vs AIRT vs ELAN

For growth investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger pick with 10. 4% revenue growth year-over-year, versus 1. 7% for Air T, Inc. (AIRT). Zoetis Inc. (ZTS) offers the better valuation at 14. 5x trailing P/E (12. 4x forward), making it the more compelling value choice. Analysts rate IDEXX Laboratories, Inc. (IDXX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zoetis Inc.

(ZTS) is the cheapest at 14. 5x versus IDEXX Laboratories, Inc. at 43. 7x. On forward P/E, Zoetis Inc. is actually cheaper at 12. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Zoetis Inc. wins at 1. 04x versus IDEXX Laboratories, Inc. 's 2. 76x — a reasonable growth-adjusted valuation.

Over the past 5 years, IDEXX Laboratories, Inc.

(IDXX) delivered a total return of +5. 1%, compared to -81. 4% for HeartBeam, Inc. (BEAT). Over 10 years, the gap is even starker: IDXX returned +556. 2% versus BEAT's -81. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Air T, Inc.

(AIRT) is the lower-risk stock at 0. 05β versus Elanco Animal Health Incorporated's 1. 42β — meaning ELAN is approximately 2826% more volatile than AIRT relative to the S&P 500. On balance sheet safety, Elanco Animal Health Incorporated (ELAN) carries a lower debt/equity ratio of 61% versus 23% for Air T, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IDEXX Laboratories, Inc.

(IDXX) is pulling ahead at 10. 4% versus 1. 7% for Air T, Inc. (AIRT). On earnings-per-share growth, the picture is similar: IDEXX Laboratories, Inc. grew EPS 22. 6% year-over-year, compared to -169. 1% for Elanco Animal Health Incorporated. Over a 3-year CAGR, AIRT leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zoetis Inc.

(ZTS) is the more profitable company, earning 28. 2% net margin versus -4. 9% for Elanco Animal Health Incorporated — meaning it keeps 28. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZTS leads at 38. 0% versus 0. 0% for BEAT. At the gross margin level — before operating expenses — ZTS leads at 70. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Zoetis Inc. (ZTS) is the more undervalued stock at a PEG of 1. 04x versus IDEXX Laboratories, Inc. 's 2. 76x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Zoetis Inc. (ZTS) trades at 12. 4x forward P/E versus 39. 5x for IDEXX Laboratories, Inc. — 27. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZTS: 63. 8% to $143. 00.

In this comparison, ZTS (2.

3% yield) pays a dividend. BEAT, IDXX, AIRT, ELAN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Air T, Inc.

(AIRT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 05)). Both have compounded well over 10 years (AIRT: +32. 1%, ELAN: -33. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BEAT (Healthcare) and IDXX (Healthcare) and ZTS (Healthcare) and AIRT (Industrials) and ELAN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BEAT is a small-cap quality compounder stock; IDXX is a mid-cap quality compounder stock; ZTS is a mid-cap deep-value stock; AIRT is a small-cap quality compounder stock; ELAN is a mid-cap quality compounder stock. ZTS pays a dividend while BEAT, IDXX, AIRT, ELAN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.